Daily Stock Analysis, BOLD, Audentes Therapeutics Inc, priceseries

Audentes Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
27.97
Close
27.31
High
27.97
Low
27.13
Previous Close
27.41
Daily Price Gain
-0.10
YTD High
28.63
YTD High Date
Sep 21, 2017
YTD Low
13.90
YTD Low Date
Jun 1, 2017
YTD Price Change
9.46
YTD Gain
53.00%
52 Week High
28.63
52 Week High Date
Sep 21, 2017
52 Week Low
13.13
52 Week Low Date
Nov 4, 2016
52 Week Price Change
11.67
52 Week Gain
74.62%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 21. 2017
17.77
Jul 26. 2017
20.93
24 Trading Days
17.76%
Link
Company Information
Stock Symbol
BOLD
Exchange
NasdaqGM
Company URL
http://www.audentestx.com
Company Phone
-
CEO
Matthew R. Patterson
Headquarters
-
Business Address
-
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001628738
About

Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.

Description

Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company is developing four products, including AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia; and AT982 for the treatment of pompe disease. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania to develop AT342, an AAV gene therapy for Crigler-Najjar Syndrome, an inherited, metabolic liver disease. The company was founded in 2012 and is based in San Francisco, California.